Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful
Links shared publicly online about this topic.
- 1,693total visits
Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful
Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").
View full resource at news-medical.net
Tags: Cancer, Lung Cancer, Lung, Drug, FDA
Most Recently Shared on October 8, 2009 at 1:01 am By:
Lung Cancer News: Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha.. http://digg.com/u1DrN8
Advertisement
